Attorney Docket No. 10577.0004-00000

Application No.: 10/542,408

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the

application:

1. (Currently amended) A method of screening a compound or its salt that changes the binding-

property of a G protein-coupled receptor protein-comprising: the same or substantially the same

amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3

or SEQ ID NO: 8, or a salt thereof, to a fatty acid or a salt thereof, which comprises using (1)

the receptor protein, its partial peptide, or a salt thereof and (2) the fatty acid or a salt thereof

(i) contacting in vitro cells comprising a G protein-coupled receptor protein comprising

substantially the same amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or

SEO ID NO: 8, wherein the G protein-coupled receptor protein has a G protein-coupled receptor

function, with a fatty acid or a salt thereof in the presence of the compound or its salt and in the

absence of the compound or its salt,

(ii) assaying a cell-stimulating activity stimulated by binding of the fatty acid or a salt thereof to

the G protein-coupled receptor protein in the presence of the compound or its salt and in the

absence of the compound or its salt, and

(iii) comparing the cell-stimulating activity stimulated by binding of the fatty acid or a salt

thereof to the G protein-coupled receptor protein in the presence of the compound or its salt and

in the absence of the compound or its salt, wherein a change in cell-stimulating activity indicates

that the compound or its salt changes a binding property of the G protein-coupled receptor

protein.

2. (Canceled)

2

Attorney Docket No. 10577.0004-00000

Application No.: 10/542,408

3. (Currently Amended) A method of Claim 1 for screening an agonist or an antagonist to a G-

protein-coupled receptor protein comprising the same or substantially the same amino acid-

sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID

NO: 8, or a salt thereof, which comprises using (1) the receptor protein, its partial peptide, or a

salt thereof and (2) a compound or its salt that changes the binding property of the receptor

protein, or a salt thereof to a fatty acid or a salt thereof. a compound or its salt comprising:

i) contacting *in vitro* a G protein-coupled receptor protein comprising substantially the same

amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, wherein

the G protein-coupled receptor protein has a G protein-coupled receptor function, with a fatty

acid or a salt thereof in the presence of the compound or its salt and in the absence of the

compound or its salt,

ii) assaying the binding of the fatty acid or a salt thereof to the G protein-coupled receptor

protein in the presence of the compound or its salt and in the absence of the compound or its salt,

and

iii) comparing the binding of the fatty acid or a salt thereof to the G protein-coupled receptor

protein in the presence of the compound or its salt and in the absence of the compound or its salt,

wherein a change in binding indicates that the compound or its salt changes a binding property of

the G protein-coupled receptor protein.

4.-13. (Canceled)

3

Application No.: 10/542,408

14. (Currently Amended) [[A]] <u>The</u> method of <u>Claim claim</u> 1, for screening an agonist to a G-protein coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, or a salt thereof, which comprises assaying wherein the cell-stimulating activity is at least one selected from [[the]] intracellular Ca<sup>2+</sup> level increasing activity, [[the]] intracellular cAMP production suppressing activity, MAP kinase phosphorylation or activation, [[the]] adrenocorticotropic hormone (ACTH) secretion suppressing activity, [[the]] glycerol production suppressing activity or [[the]] lipolysis suppressing activity, in the case where a test compound is contacted with cells containing a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 8, or a salt thereof:

15.-77. (Canceled)

78. (New) The method of claim 1, wherein the compound is an agonist or antagonist to a G protein-coupled receptor protein.

79. (New) The method of claim 3, wherein the compound is an agonist or antagonist to a G protein-coupled receptor protein.

80. (New) The method of claim 14, wherein the compound is an agonist or antagonist to a G protein-coupled receptor protein.